MDCX
Medicus Pharma Ltd.
$0.3350
+4.69%
$18.5M
No data for this timeframe.
Vol
Market Cap$18.5M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders6 funds
Inst. Value$50.1K
Inst. Activity1 buys / 1 sells
Reddit Sentiment47° Neutral
Press Releases7
Recent Activity
Jun 3, 2026
Insider
Brennan Edward J. was granted 25,000 shares
Chief Scientific Officer
Jun 3, 2026
Insider
Bokhari Raza was granted 500,000 shares
Chief Executive Officer
Jun 3, 2026
Insider
Ashton William was granted 50,000 shares
Director
Inst.
COMMONWEALTH EQUITY SERVICES, LLC — ADD
48,143 shares ($22.1K)
Inst.
MORGAN STANLEY — TRIM
5,468 shares ($2.5K)
Jun 15, 2026
other
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
Submission Supports Development of a Potential Non-Surgical Treatment for a Rare Genetic Disorder th
May 14, 2026
Press
Medicus Pharma reported Q1 2026 results with a net loss of $9.0M (vs. $5.1M a year ago), cash of $6.4M, and disclosed su
Impact 6/10
May 6, 2026
Press
Medicus Pharma announced positive dose-response results from an expanded analysis of its Phase 2 SKNJCT-003 study for Do
Impact 7/10
Price Targets
$5.67
+1592.0% upside
Strong Buy
Current $0.3349
Low $2.00
Median $6.00
High $9.00
3 analysts
$2.00
$9.00
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 20, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Mar 19, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Mar 9, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.16 ▲ +13.5% | $-0.16 — $-0.16 | 62% YoY | 1 |
| Next Q | $-0.10 ▲ +33.3% | $-0.12 — $-0.08 | 91% YoY | 2 |
| Current FY | $-0.54 ▲ +14.3% | $-0.54 — $-0.54 | 73% YoY | 1 |
| Next FY | $-0.39 | $-0.40 — $-0.38 | 30% YoY | 2 |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| COMMONWEALTH EQUITY SERVICES, LLC | $22.1K | ADD |
| BlackRock, Inc. | $17.1K | DOUBLED |
| CITADEL ADVISORS LLC | $8.2K | — |
| MORGAN STANLEY | $2.5K | TRIM |
| JONES FINANCIAL COMPANIES LLLP | $180.00 | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Brennan Edward | A | $0.00 |
| Jun 3, 2026 | Bokhari Raza | A | $0.00 |
| Jun 3, 2026 | Ashton William | A | $0.00 |
| Jun 3, 2026 | Bonner Carolyn | A | $0.00 |
| Jun 3, 2026 | Ciaruffoli Robert | A | $0.00 |
Reddit Sentiment
47°▼
Neutral
Bearish
Neutral
Bullish
6 institutional holders with $50.1K total value (109,204 shares) as of 2026-Q1. Top holders: COMMONWEALTH, BlackRock,, CITADEL.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | COMMONWEALTH EQUITY SERVICES, LLC | 48,143 | $22.1K | 44.1% | ADD +69.0% |
| 2 | BlackRock, Inc. | 37,294 | $17.1K | 34.2% | DOUBLED +111.6% |
| 3 | CITADEL ADVISORS LLC | 17,824 | $8.2K | 16.3% | — |
| 4 | MORGAN STANLEY | 5,468 | $2.5K | 5.0% | TRIM -70.1% |
| 5 | JONES FINANCIAL COMPANIES LLLP | 400 | $180.00 | 0.4% | — |
| 6 | WELLS FARGO & COMPANY/MN | 75 | $34.00 | 0.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| COMMONWEALTH EQUITY SERVICES, LLC | ADD | 28,493 | 48,143 | +69.0% | $22.1K | 2026-Q1 |
| MORGAN STANLEY | TRIM | 18,306 | 5,468 | -70.1% | $2.5K | 2026-Q1 |
| BlackRock, Inc. | DOUBLED | 16,216 | 34,317 | +111.6% | $52.5K | 2025-Q4 |
| COMMONWEALTH EQUITY SERVICES, LLC | DOUBLED | 10,882 | 28,493 | +161.8% | $43.6K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 5,968 | 18,306 | +206.7% | $28.0K | 2025-Q4 |
| UBS Group AG | NEAR_EXIT | 30,926 | 6,957 | -77.5% | $16.1K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 11,730 | 5,968 | -49.1% | $13.8K | 2025-Q3 |
| UBS Group AG | ADD | 21,262 | 30,926 | +45.5% | $92.5K | 2025-Q2 |
13 unique insiders with 26 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Brennan Edward J. | Chief Scientific Officer | AWARD | 25,000 | — | — |
| Jun 3, 2026 | Bokhari Raza | Chief Executive Officer | AWARD | 500,000 | — | — |
| Jun 3, 2026 | Ashton William | Director | AWARD | 50,000 | — | — |
| Jun 3, 2026 | Bonner Carolyn F. | President and CFO | AWARD | 250,000 | — | — |
| Jun 3, 2026 | Ciaruffoli Robert J. | Director | AWARD | 50,000 | — | — |
| Jun 3, 2026 | FISHMAN BARRY | Director | AWARD | 50,000 | — | — |
| Jun 3, 2026 | Kaiser Larry | Director | AWARD | 50,000 | — | — |
| Jun 3, 2026 | May Sara R. | Director | AWARD | 50,000 | — | — |
| Jun 3, 2026 | MAHAFFY PATRICK J | Director | AWARD | 50,000 | — | — |
| Jun 3, 2026 | Raju Ajay | Director | AWARD | 50,000 | — | — |
| Jun 3, 2026 | Mehmud Faisal | Chief Medical Officer | AWARD | 250,000 | — | — |
| Jun 3, 2026 | Smith Andrew Alasdair | Chief Operating Officer | AWARD | 200,000 | — | — |
| Jun 3, 2026 | Rodgers Cathy McMorris | Director | AWARD | 50,000 | — | — |
| Mar 30, 2026 | Ashton William | Director | AWARD | 25,000 | — | — |
| Mar 30, 2026 | Brennan Edward J. | Chief Scientific Officer | AWARD | 25,000 | — | — |
| Mar 30, 2026 | Bokhari Raza | Chief Executive Officer | AWARD | 325,000 | — | — |
| Mar 30, 2026 | Bonner Carolyn F. | President and CFO | AWARD | 100,000 | — | — |
| Mar 30, 2026 | Ciaruffoli Robert J. | Director | AWARD | 25,000 | — | — |
| Mar 30, 2026 | FISHMAN BARRY | Director | AWARD | 25,000 | — | — |
| Mar 30, 2026 | Kaiser Larry | Director | AWARD | 25,000 | — | — |
| Mar 30, 2026 | MAHAFFY PATRICK J | Director | AWARD | 25,000 | — | — |
| Mar 30, 2026 | May Sara R. | Director | AWARD | 25,000 | — | — |
| Mar 30, 2026 | Mehmud Faisal | Chief Medical Officer | AWARD | 125,000 | — | — |
| Mar 30, 2026 | Smith Andrew Alasdair | Chief Operating Officer | AWARD | 50,000 | — | — |
| Mar 30, 2026 | Raju Ajay | Director | AWARD | 25,000 | — | — |
| Mar 30, 2026 | Rodgers Cathy McMorris | Director | AWARD | 25,000 | — | — |
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
BEARISH
6/10
Medicus Pharma reported Q1 2026 results with a net loss of $9.0M (vs. $5.1M a year ago), cash of $6.
May 14, 2026
BULLISH
7/10
Medicus Pharma announced positive dose-response results from an expanded analysis of its Phase 2 SKN
May 6, 2026
NEUTRAL
4/10
Medicus Pharma announced the submission of an optimized Phase 2 clinical trial design for Teverelix,
Apr 6, 2026
BULLISH
7/10
Medicus Pharma clarified its Phase 2 topline data for SkinJect-003 in nodular basal cell carcinoma,
Apr 1, 2026
BULLISH
8/10
Medicus Pharma announced positive Phase 2 results for its SkinJect microneedle-delivered doxorubicin
Mar 16, 2026
BULLISH
8/10
Medicus Pharma (MDCX) released updated topline data from its Phase 2 SKNJCT-003 trial showing 73% cl
Mar 9, 2026
BULLISH
8/10
Medicus Pharma (MDCX) announced positive topline results from its Phase 2 SKNJCT-003 trial of D-MNA,
Mar 5, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.67 mean target
+1592.0% upside
Strong Buy (1.33)
$2.00 Low
$9.00 High
| Metric | Value |
|---|---|
| Current Price | $0.3349 |
| Target Low | $2.00 |
| Target Mean | $5.67 |
| Target Median | $6.00 |
| Target High | $9.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (1.33) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.16 | $-0.16 | $-0.16 | 61.8% | +13.5% | — | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.10 | $-0.12 | $-0.08 | 91.1% | +33.3% | 2↑ 0↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-0.54 | $-0.54 | $-0.54 | 73.0% | +14.3% | — | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-0.39 | $-0.40 | $-0.38 | 29.7% | +0.0% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.160 | |
| 7d ago | $-0.185 | +0.025 |
| 30d ago | $-0.185 | +0.025 |
| 60d ago | $0.000 | -0.160 |
| 90d ago | $0.000 | -0.160 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 20, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 19, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 9, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
47°
Neutral
Bearish
Neutral
Bullish
13 mentions
3 bullish
4 bearish
13 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 4, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 4, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 7, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 6, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 6, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 27, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 27, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 25, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 25, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
| Mar 22, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 22, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 19, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 19, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
$MDCX(Medicus Pharma — $22M non-dilutive financing secured, multiple clinical catalysts ahead on a sub $1 biotech
▲ 1
💬 1
⚡ 0.5
MDCX, Hop in for 4,000%+
▲ 1
💬 1
⚡ 0.5
MDCX breakout isn’t random: Teverelix just turned this into a real multi-shot biotech
▲ 17
💬 1
⚡ 0.7
MDCX still got a little life yet
▲ 1
💬 0
⚡ 0.5
MDCX looks way too cheap heading into tomorrow’s webcast
▲ 1
💬 1
⚡ 0.5
Example of how low float momentum works (MDCX)
▲ 1
💬 0
⚡ 0.5
Jun 15, 2026
other
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome
Submission Supports Development of a Potential Non-Surgical Treatment for a Rare Genetic Disorder that Causes Recurrent Basal Cell Carcinomas Beginnin
Jun 11, 2026
other
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
Novel genomics-enabled clinical trial in United Arab Emirates (UAE) seeks to identify genetic predictors of treatment response while evaluating Tevere
Jun 8, 2026
other
Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission
European regulatory filing supports planned 2026 initiation of Phase 2b study of Teverelix® in an underserved population representing ~$4 billion annu
Jun 5, 2026
short_volume
Short Volume: MDCX — 61.8% short (0.6M / 1.0M)
Short: 636,575 | Exempt: 149,287 | TRF Vol: 1,029,477 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: MDCX — 55.5% short (2.6M / 4.6M)
Short: 2,576,057 | Exempt: 22,672 | TRF Vol: 4,644,827 | Short Ratio: 55.5% | Off-exchange volume (dark pool + OTC)
May 28, 2026
other
Medicus Pharma Announces $22 Million Non-Dilutive Financing
Financing Provides Immediate Growth Capital to Support Clinical Development Initiatives and Extends Projected Operating Cash Runway for Over Two (2) Y
May 20, 2026
short_volume
Short Volume: MDCX — 55.4% short (0.3M / 0.6M)
Short: 339,422 | Exempt: 0 | TRF Vol: 612,812 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: MDCX — 59.8% short (0.4M / 0.6M)
Short: 383,566 | Exempt: 73,399 | TRF Vol: 640,954 | Short Ratio: 59.8% | Off-exchange volume (dark pool + OTC)
May 14, 2026
announcement
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
Company Advances SkinJect® and Teverelix® Clinical Programs While Strengthening Financing Flexibility and Expanding Strategic Development Initiatives
May 13, 2026
earnings_calendar
MDCX Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings_calendar
MDCX Q1 2026 Earnings Scheduled — 2026-05-11
May 11, 2026
short_volume
Short Volume: MDCX — 62.2% short (0.8M / 1.3M)
Short: 797,086 | Exempt: 4,739 | TRF Vol: 1,281,261 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
May 8, 2026
short_volume
Short Volume: MDCX — 56.6% short (1.0M / 1.8M)
Short: 1,007,695 | Exempt: 7,776 | TRF Vol: 1,778,822 | Short Ratio: 56.6% | Off-exchange volume (dark pool + OTC)
May 6, 2026
fda
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
200µg Cohort Achieves 55% Complete Response at Day 57 Emerging as Registrational Grade Lead Regimen <pre>200µg Cohort Achieves 55% Complete Response a
May 6, 2026
short_volume
Short Volume: MDCX — 55.1% short (3.6M / 6.6M)
Short: 3,639,797 | Exempt: 550,932 | TRF Vol: 6,606,153 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)